Heterogeneity of HER2 expression in gastric cancer (GC) leads to high deviation rates between local and central testing and hampers efficacy of anti-HER2 therapy: Survival results from the VARIANZ study

F Lordick; I Haffner; B Luber; D Maier; E Raimundez; J Hasenauer; A Kretzschmar; LF von Weikersthal; M Ahlborn; JR Knorrenschild; Gabriele Siegler; B Rau; S Fuxius; T Decker; K Schierle; C Wittekind

doi:10.1158/1538-7445.AM2018-2615

Heterogeneity of HER2 expression in gastric cancer (GC) leads to high deviation rates between local and central testing and hampers efficacy of anti-HER2 therapy: Survival results from the VARIANZ study

F Lordick, I Haffner, B Luber, D Maier, E Raimundez, J Hasenauer, A Kretzschmar, LF von Weikersthal, M Ahlborn, JR Knorrenschild, Gabriele Siegler, B Rau, S Fuxius, T Decker, K Schierle, C Wittekind

Department of Internal Medicine V, Division of Oncology and Hematology

Research output: Contribution to journal › Abstract (Journal) › peer-review

2 Citations (Web of Science)

Original language	English
Journal	CANCER RESEARCH
Volume	78
Issue number	13
DOIs	https://doi.org/10.1158/1538-7445.AM2018-2615
Publication status	Published - 2018
Event	Annual Meeting of the American-Association-for-Cancer-Research (AACR) - Chicago, IL Duration: 14 Apr 2018 → 18 Apr 2018

Access to Document

10.1158/1538-7445.AM2018-2615

Cite this

Lordick, F., Haffner, I., Luber, B., Maier, D., Raimundez, E., Hasenauer, J., Kretzschmar, A., von Weikersthal, LF., Ahlborn, M., Knorrenschild, JR., Siegler, G., Rau, B., Fuxius, S., Decker, T., Schierle, K., & Wittekind, C. (2018). Heterogeneity of HER2 expression in gastric cancer (GC) leads to high deviation rates between local and central testing and hampers efficacy of anti-HER2 therapy: Survival results from the VARIANZ study. CANCER RESEARCH , 78(13). https://doi.org/10.1158/1538-7445.AM2018-2615

Lordick, F ; Haffner, I ; Luber, B et al. / Heterogeneity of HER2 expression in gastric cancer (GC) leads to high deviation rates between local and central testing and hampers efficacy of anti-HER2 therapy: Survival results from the VARIANZ study. In: CANCER RESEARCH 2018 ; Vol. 78, No. 13.

@article{a6674a5919984a319bd7bd68c5662c30,

title = "Heterogeneity of HER2 expression in gastric cancer (GC) leads to high deviation rates between local and central testing and hampers efficacy of anti-HER2 therapy: Survival results from the VARIANZ study",

author = "F Lordick and I Haffner and B Luber and D Maier and E Raimundez and J Hasenauer and A Kretzschmar and {von Weikersthal}, LF and M Ahlborn and JR Knorrenschild and Gabriele Siegler and B Rau and S Fuxius and T Decker and K Schierle and C Wittekind",

year = "2018",

doi = "10.1158/1538-7445.AM2018-2615",

language = "English",

volume = "78",

journal = "CANCER RESEARCH ",

issn = "0008-5472",

publisher = "Amer Assoc Cancer Research",

number = "13",

note = "Annual Meeting of the American-Association-for-Cancer-Research (AACR) ; Conference date: 14-04-2018 Through 18-04-2018",

}

Lordick, F, Haffner, I, Luber, B, Maier, D, Raimundez, E, Hasenauer, J, Kretzschmar, A, von Weikersthal, LF, Ahlborn, M, Knorrenschild, JR, Siegler, G, Rau, B, Fuxius, S, Decker, T, Schierle, K & Wittekind, C 2018, 'Heterogeneity of HER2 expression in gastric cancer (GC) leads to high deviation rates between local and central testing and hampers efficacy of anti-HER2 therapy: Survival results from the VARIANZ study', CANCER RESEARCH , vol. 78, no. 13. https://doi.org/10.1158/1538-7445.AM2018-2615

Heterogeneity of HER2 expression in gastric cancer (GC) leads to high deviation rates between local and central testing and hampers efficacy of anti-HER2 therapy: Survival results from the VARIANZ study. / Lordick, F; Haffner, I; Luber, B et al.
In: CANCER RESEARCH , Vol. 78, No. 13, 2018.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Heterogeneity of HER2 expression in gastric cancer (GC) leads to high deviation rates between local and central testing and hampers efficacy of anti-HER2 therapy: Survival results from the VARIANZ study

AU - Lordick, F

AU - Haffner, I

AU - Luber, B

AU - Maier, D

AU - Raimundez, E

AU - Hasenauer, J

AU - Kretzschmar, A

AU - von Weikersthal, LF

AU - Ahlborn, M

AU - Knorrenschild, JR

AU - Siegler, Gabriele

AU - Rau, B

AU - Fuxius, S

AU - Decker, T

AU - Schierle, K

AU - Wittekind, C

PY - 2018

Y1 - 2018

U2 - 10.1158/1538-7445.AM2018-2615

DO - 10.1158/1538-7445.AM2018-2615

M3 - Abstract (Journal)

SN - 0008-5472

VL - 78

JO - CANCER RESEARCH

JF - CANCER RESEARCH

IS - 13

T2 - Annual Meeting of the American-Association-for-Cancer-Research (AACR)

Y2 - 14 April 2018 through 18 April 2018

ER -

Lordick F, Haffner I, Luber B, Maier D, Raimundez E, Hasenauer J et al. Heterogeneity of HER2 expression in gastric cancer (GC) leads to high deviation rates between local and central testing and hampers efficacy of anti-HER2 therapy: Survival results from the VARIANZ study. CANCER RESEARCH . 2018;78(13). doi: 10.1158/1538-7445.AM2018-2615